Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLENO study of switching Portuguese patients with relapsing-remitting multiple sclerosis from subcutaneous interferon to Plegridy
2016-000434-21Phase 4Completed
- Sponsor
- Biogen
- Start
- Sep 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon beta, interferon beta-1a and interferon beta-1b in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Combined counts of flu-like symptom, injection site reaction, and injection site reaction pain adverse events. Started Sep 2016; status: completed.
02
Drugs
interferon betainterferon beta-1ainterferon beta-1b
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-000434-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000434-21.